Research

Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly


Reference:

Braun, J., McHugh, N. J., Singh, A., Wajdula, J. S. and Sato, R., 2007. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology, 46 (6), pp. 999-1004.

Related documents:

This repository does not currently have the full-text of this item.
You may be able to access a copy if URLs are provided below.

Official URL:

http://dx.doi.org/10.1093/rheumatology/kem069

Abstract

The more convenient etanercept 50 mg QW dose regimen significantly improves function and QOL in patients with AS, similarly to the standard dosing of 25 mg BIW, supporting its use for AS therapy.

Details

Item Type Articles
CreatorsBraun, J., McHugh, N. J., Singh, A., Wajdula, J. S. and Sato, R.
DOI10.1093/rheumatology/kem069
DepartmentsFaculty of Science > Pharmacy & Pharmacology
Faculty of Humanities & Social Sciences > Health
RefereedYes
StatusPublished
ID Code27954

Export

Actions (login required)

View Item